Biblio
Export 1939 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is B [Clear All Filters]
“The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.”, J Alzheimers Dis, 2015.
, “Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 47, no. 1, pp. 167-76, 2015.
, “Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 48, no. 1, pp. 205-18, 2015.
, “Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 48, no. 1, pp. 205-18, 2015.
, “Divalent Copper as a Major Triggering Agent in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Identification of Novel Tau Interactions with Endoplasmic Reticulum Proteins in Alzheimer's Disease Brain.”, J Alzheimers Dis, 2015.
, “Impairment of Age Estimation from Faces in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “Impairment of Age Estimation from Faces in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “A Novel Plasma Based Biomarker of Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 3, pp. 761-71, 2015.
, “A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
, “sAβPPα is a Potent Endogenous Inhibitor of BACE1.”, J Alzheimers Dis, vol. 47, no. 3, pp. 545-55, 2015.
, “Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 47, no. 1, pp. 231-42, 2015.
, , “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
,